Xenomics Appoints New CEO

Xenomics, Inc. has announced the appointment of Company co-founder L. David Tomei, Ph.D., as new CEO. Dr. Tomei will remain in his post as co-Chairman. He replaces former CEO V. Randy White, Ph.D., who has left the Company to pursue other interests.

The appointment of Dr. Tomei to the senior management position is the latest step in the Company's strategic plan to commercialize its patented Transrenal-DNA (Tr-DNA) technology as a basis to develop an extensive suite of noninvasive DNA-based diagnostic tests for a wide range of major diseases, genetic disorders and other serious health care conditions. Tr-DNA can be obtained through urine samples.

Dr. Tomei, a research scientist and veteran biotechnology industry entrepreneur and chief executive, co-founded Xenomics with Dr. Samuil Umansky, the Company's President and Chief Scientific Officer.

"Xenomics has entered an exciting period as we continue clinical studies and move toward the development of what we believe will be an entirely new class of medical diagnostics tests," said Dr. Tomei.

"The diagnostic testing products we are developing have the potential to provide enormous benefit for people worldwide by making it possible for health care professionals to diagnose everything from cancer and tuberculosis, to prenatal conditions in a painless, safe and fully accurate way."

"The Company is focused on bringing a range of new medical diagnostic testing products to market based on the unique platform technology of Tr-DNA."

Xenomics claims that, using a simple and convenient urine sample, Tr-DNA can provide important medical information about conditions inside the body, including but not limited to fetal development during pregnancy, cancer and serious infectious diseases.